Clinical trial IJB_3116
A Phase 3 Multicenter, Randomized, Open-label, Active-controlled, Study of AMG 510 versus Docetaxel for the treatment of Previously treated locally Advanced and unresectable or Metastatic NSCLC Subjects with mutated KRAS p.G12C
Cancers | |
---|---|
Organ | Lung |
Trial status | Trial closed for recruitment |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 3 |
Academic trial | Non |
Sponsor | Amgen |
EudraCT Identifier | 2019-003582-18 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04303780 |
Inclusion criteria | NSCLC |
Last update |